Korean Diabetes J.  2008 Jun;32(3):224-235. 10.4093/kdj.2008.32.3.224.

Adiponectin Concentrations in Type 2 Diabetic Patients with or without Metabolic Syndrome

Affiliations
  • 1Division of Endocrinology and Metabolism, Department of Internal Medicine, Dong-A University Medical Center, Korea.
  • 2Department of Pharmacology, College of Medicine, Dong-A University, Korea.
  • 3Department of Medicine, Dong-A University Graduate School, Korea.
  • 4Diabetes Center, Dong-A University Medical Sciences Research Institute, Korea.
  • 5Department of Internal Medicine, Hyosung City Hospital, Korea.
  • 6Department of Internal Medicine, Hanseo Hospital, Korea.

Abstract

BACKGROUND: Adipocytes produce several adipokines that modulate insulin action as well as glucose and lipid metabolism. The aim of this study was to evaluate the relationship between serum adiponectin concentrations and metabolic syndrome (MS) in patients with type 2 diabetes mellitus.
METHODS
This study included 127 type 2 diabetic patients (males 63, females 64). The subjects were divided into two groups as with or without metabolic syndrome (MS(+) or MS(-)). The MS was diagnosed by International Diabetes Federation. Serum adiponectin, leptin, fasting plasma insulin, glucose, glycated hemoglobin, lipid profile, white blood corpuscle (WBC), aspartate aminotransferase (AST), alanine aminotransferase (ALT), uric acid and C-reactive protein (CRP) were examined.
RESULTS
Serum adiponectin concentrations were significantly lower in MS(+) than MS(-) (4.8 +/- 2.4 microgram/mL vs 7.6 +/- 5.8 microgram/mL, 7.6 +/- 3.7 microgram/mL vs 11.5 +/- 7.2 microgram/mL, P < 0.05 in males and females). After adjustment for age and body mass index (BMI), in MS (+), the serum levels of adiponectin correlated positively with high density lipoprotein - cholesterol (HDL-C) and negatively with height, body weight, ALT and CRP. In MS(-), the serum levels of adiponectin correlated positively with HDL-C and negatively with diastolic blood pressure (DBP), triglyceride and CRP. By multiple regression analysis, no parameters were independently correlated with serum adiponectin concentrations in MS(+), while DBP and HDL-C were independently related to serum adiponectin concentrations in MS(-).
CONCLUSION
Serum adiponectin concentrations were lower in type 2 diabetic patients with MS than without MS. There were no significant parameters related to decrease serum adiponectin concentrations in MS. But further study is needed to confirm this result.

Keyword

Adiponectin; Metabolic syndrome; Type 2 diabetes

MeSH Terms

Adipocytes
Adipokines
Adiponectin
Alanine Transaminase
Aspartate Aminotransferases
Blood Pressure
Body Height
Body Mass Index
C-Reactive Protein
Cholesterol
Fasting
Female
Glucose
Hemoglobins
Humans
Insulin
Leptin
Leukocytes
Lipid Metabolism
Lipoproteins
Male
Plasma
Uric Acid
Adipokines
Adiponectin
Alanine Transaminase
Aspartate Aminotransferases
C-Reactive Protein
Cholesterol
Glucose
Hemoglobins
Insulin
Leptin
Lipoproteins
Uric Acid

Figure

  • Fig. 1 Serum adiponectin and leptin concectrations in type 2 diabetic patients with metabolic syndrome (MS(+)) and without metabolic syndrome (MS(-)). *P < 0.05 vs MS(-).

  • Fig. 2 Serum adiponectin concentrations in subgroups of metabolic syndrome (MS) (panel A). MS(+) HT presents the subgroup of MS with raised blood pressure. MS(+) Dys presents the subgroup of MS with hypertriglyceridaemia and/or low HDL-cholesterol, MS(+) HT+Dys is the subgroup of MS with raised blood pressure and hypertriglyceridaemia and/or low HDL-cholesterol. The serum level of MS(-) was significantly increased than that of each subgroup in MS(+). *P < 0.05 vs MS(+). Serum adiponectin concentrations in MS(+) Dys subgroups (panel B). Dys (TG) presents the subgroup of MS with hypertriglyceridaemia. Dys (HDL) presents the subgroup of MS with low HDL-cholesterol. Dys (TG&HDL) presents the subgroup of MS with hypertriglyceridaemia and low HDL-cholesterol. The serum adiponectin concentrations of each subgroup in MS(+) Dys group were not significantly different between them.


Cited by  3 articles

The Effects of 12-Weeks Intensive Intervention Program on Cardiovascular Risk Factors, Adipocytokines and Nutrients Intakes in Industrial Male Workers
Kieun Moon, Ill Keun Park, Yeon Sang Jo, Yun Kyun Chang, Yun Mi Paek, Tae In Choi
Korean J Nutr. 2011;44(4):292-302.    doi: 10.4163/kjn.2011.44.4.292.

Relationship between Nutrients Intakes, Dietary Quality, and Serum Concentrations of Inflammatory Markers in Metabolic Syndrome Patients
Misung Kim, Juyoung Kim, Wookyung Bae, Sohye Kim, Yesong Lee, Woori Na, Cheongmin Sohn
Korean J Community Nutr. 2011;16(1):51-61.    doi: 10.7469/KJCN.2011.16.1.51.

Prevalence of Pancreatic Cancer in Diabetics and Clinical Characteristics of Diabetes-associated with Pancreatic Cancer - Comparison between Diabetes with and without Pancreatic Cancer -
Seung Goun Hong, Jae Seon Kim, Sung Joo Jung, Moon Kyung Joo, Beom Jae Lee, Jong Eun Yeon, Jong-Jae Park, Kwan Soo Byun, Young-Tae Bak
Korean J Gastroenterol. 2009;54(3):167-173.    doi: 10.4166/kjg.2009.54.3.167.


Reference

1. Ahima RS, Flier JS. Adipose tissue as an endocrine organ. Trends Endocrinol Metab. 2000. 11:327–332.
Article
2. Shimomura I, Funahashi T, Takahashi M, Maeda K, Kotani K, Nakamura T, Yamashita S, Miura M, Fukuda Y, Takemura K, Tokunaga K, Matsuzawa Y. Enhanced expression of PAI-1 in visceral fat: possible contributor to vascular disease in obesity. Nat Med. 1996. 2:800–803.
3. Spiegelman BM, Flier JS. Adipogenesis and obesity: rounding out the big picture. Cell. 1996. 87:377–389.
Article
4. Tsao TS, Murrey HE, Hug C, Lee DH, Lodish HF. Oligomerization state-dependent activation of NF-kappa B signaling pathway by adipocyte complement-related protein of 30 kDa (Acrp30). J Biol Chem. 2002. 277:29359–29362.
5. Krakoff J, Funahashi T, Stehouwer CD, Schalkwijk CG, Tanaka S, Matsuzawa Y, Kobes S, Tataranni PA, Hanson RL, Knowler WC, Lindsay RS. Inflammatory markers, adiponectin, and risk of type 2 diabetes in the Pima Indian. Diabetes Care. 2003. 26:1745–1751.
Article
6. Weyer C, Funahashi T, Tanaka S, Hotta K, Matsuzawa Y, Pratley RE, Tataranni PA. Hypoadiponectinemia in obesity and type 2 diabetes: close association with insulin resistance and hyperinsulinemia. J Clin Endocrinol Metab. 2001. 86:1930–1935.
Article
7. Cnop M, Havel PJ, Utzschneider KM, Sinha MK, Boyko EJ, Retzlaff BM, Knopp RH, Brunzell JD, Kahn SE. Relationship of adiponectin to body fat distribution, insulin sensitivity and plasma lipoproteins: evidence for independent roles of age and sex. Diabetologia. 2003. 46:459–469.
Article
9. Hotta K, Funahashi T, Arita Y, Takahashi M, Matsuda M, Okamoto Y, Iwahashi H, Kuriyama H, Ouchi N, Maeda K, Nishida M, Kihara S, Sakai N, Nakajima T, Hasegawa K, Muraguchi M, Ohmoto Y, Nakamura T, Yamashita S, Hanafusa T, Matsuzawa Y. Plasma concentrations of a novel, adipose-specific protein, adiponectin, in type 2 diabetic patients. Arterioscler Thromb Vasc Biol. 2000. 20:1595–1599.
Article
11. Choi KM, Ryu OH, Lee KW, Kim HY, Seo JA, Kim SG, Kim NH, Choi DS, Baik SH. Serum adiponectin, interleukin-10 levels and inflammatory markers in the metabolic syndrome. Diabetes Res Clin Pract. 2007. 75:235–240.
Article
12. Kim SM, Cho KH, Park HS. Relationship between plasma adiponectin levels and the metabolic syndrome. Endocr J. 2006. 53:247–254.
13. Jang Y, Lee JH, Kim OY, Koh SJ, Chae JS, Woo JH, Cho H, Lee JE, Ordovas JM. The SNP276G>T polymorphism in the adiponectin (ACDC) gene is more strongly associated with insulin resistance and cardiovascular disease risk than SNP45T>G in nonobese/nondiabetic Korean men independent of abdominal adiposity and circulating plasma adiponectin. Metabolism. 2006. 55:59–66.
14. Choi KM, Lee J, Lee KW, Seo JA, Oh JH, Kim SG, Kim NH, Choi DS, Baik SH. Serum adiponectin concentrations predict the developments of type 2 diabetes and the metabolic syndrome in elderly Koreans. Clin Endocrinol. 2004. 61:75–80.
Article
15. Cruz M, Garcia-Macedo R, Garcia-Valerio Y, Gutierrez M, Medina-Navarro R, Duran G, Wacher N, Kumate J. Low adiponectin levels predict type 2 diabetes in Mexican children. Diabetes Care. 2004. 27:1451–1453.
Article
16. Yamamoto Y, Hirose H, Saito I, Nishikai K, Saruta T. Adiponectin, an adipocyte-derived protein, predicts future insulin resistance: two year follow-up study in Japanese population. J Clin Endocrinol Metab. 2004. 89:87–90.
17. HOMA Calculator v2.2. Diabetes Trials Unit, Oxford, URL. 2004. accessed March 22 2005. http://www.dtu.ox.ac.uk/index.html/maindoc/publications/.
18. Friedewald WT, Levy RT, Fredrickson DS. Estimation of the concentration of low density lipoprotein cholesterol in plasma without use of the ultracentrifuge. Clin Chem. 1972. 18:449502.
19. The IDF consensus worldwide definition of the metabolic syndrome. International Diabetes Federation. 2005. 04. 14. accessed June 10, 2005. http://www.idf.org/webdata/docs/IDF_ Metasyndrome_definition.pdf.
20. Maeda N, Takahashi M, Funahashi T, Kihara S, Nishizawa H, Kishida K, Nagaretani H, Matsuda M, Komuro R, Ouchi N, Kuriyama H, Hotta K, Nakamura T, Shimomura I, Matsuzawa Y. PPARg ligands increase expression and plasma concentrations of adiponectin, an adipose-derived protein. Diabetes. 2001. 50:20949.
21. Fasshauer M, Klein J, Neumann S, Eszlinger M, Paschke R. Hormonal regulation of adiponectin gene expression in 3T3-L1adipocytes. Biochem Biophys Res Commun. 2002. 290:10849.
22. Halleux CM, Takahashi M, Delporte ML, Detry R, Funahashi T, Matsuzawa Y, Brichard SM. Secretion of adiponectin and regulation of apM1 gene expression in human visceral adipose tissue. Biochem Biophys Res Commun. 2001. 288:11027.
Article
23. Motoshima H, Wu X, Sinha MK, Hardy VE, Rosato EL, Barbot DJ, Rosato FE, Goldstein BJ. Differential regulation of adiponectin secretion from cultured human omental and subcutaneous adipocytes: effects of insulin and rosiglitazone. J Clin Endocrinol Metab. 2002. 87:56627.
Article
24. Yu JG, Javorschi S, Hevener AL, Kruszynska YT, Norman RA, Sinha M, Olefsky JM. The effect of thiazolidinediones on plasma adiponectin levels in normal, obese, and type 2 diabetic subjects. Diabetes. 2002. 51:296874.
Article
25. Hulver MW, Zheng D, Tanner CJ, Houmard JA, Kraus WE, Slentz CA, Sinha MK, Pories WJ, MacDonald KG, Dohm GL. Adiponectin is not altered with exercise training despite enhanced insulin action. Am J Physiol Endocrinol Metab. 2002. 283:8615.
26. Abbasi F, Lamendola C, McLaughlin T, Hayden J, Reaven GM, Reaven PD. Plasma adiponectin concentrations do not increase in association with moderate weight loss in insulin resistant, obese women. Metabolism. 2004. 53:2803.
27. Fasshauer M, Klein J, Neumann S, Eszlinger M, Paschke R. Adiponectin gene expression is inhibited by beta-adrenergic stimulation via protein kinase A in 3T3-L1 adipocytes. FEBS Lett. 2001. 507:1426.
28. Fasshauer M, Kralisch S, Klier M, Lossner U, Bluher M, Klein J, Paschke R. Adiponectin gene expression and secretion is inhibited by interleukin-6 in 3T3-L1 adipocytes. Biochem Biophys Res Commun. 2003. 301:104550.
Article
29. Kumada M, Kihara S, Sumitsuji S, Kawamoto T, Matsumoto S, Ouchi N, Arita Y, Okamoto Y, Shimomura I, Hiraoka H, Nakamura T, Funahashi T, Matsuzawa Y. Osaka CAD Study Group, Coronary artery disease. Association of hypoadiponectinemia with coronary artery disease in men. Arterioscler Thromb Vasc Biol. 2003. 23:85–89.
Article
30. Mallamaci F, Zoccali C, Cuzzola F, Tripepi G, Cutrupi S, Parlongo S, Tanaka S, Ouchi N, Kihara S, Funahashi T, Matsuzawa Y. Adiponectin in essential hypertension. J Nephrol. 2002. 15:507–511.
31. Zoccali C, Mallamaci F, Tripepi G, Benedetto FA, Cutrupi S, Parlongo S, Malatino LS, Bonanno G, Seminara G, Rapisarda F, Fatuzzo P, Buemi M, Nicocia G, Tanaka S, Ouchi N, Kihara S, Funahashi T, Matsuzawa Y. Adiponectin, metabolic risk factors, and cardiovascular events among patients with end-stage renal disease. J Am Soc Nephrol. 2002. 13:134–141.
Article
32. Kumada M, Kihara S, Ouchi N, Kobayashi H, Okamoto Y, Ohashi K, Maeda K, Nagaretani H, Kishida K, Maeda N, Nagasawa A, Funahashi T, Matsuzawa Y. Adiponectin specifically increased tissue inhibitor ofmetalloproteinase-1 through interleukin-10 expression in human macrophages. Circulation. 2004. 109:2046–2049.
33. Arita Y, Kihara S, Ouchi N, Maeda K, Kuriyama H, Okamoto Y, Kumada M, Hotta K, Nishida M, Takahashi M, Nakamura T, Shimomura I, Muraguchi M, Ohmoto Y, Funahashi T, Matsuzawa Y. Adipocyte derived plasma protein adiponectin acts as a platelet-derived growth factor-BB-binding protein and regulates growth factor-induced common postreceptor signal in vascular smooth muscle cell. Circulation. 2002. 105:2893–2898.
34. Matsubara M, Maruoka S, Katayose S. Decreased plasma adiponectin concentrations in women with dyslipidemia. J Clin Endocrinol Metab. 2002. 87:2764–2769.
Article
35. Nishzawa T, Shimomura I, Kishida K, Maeda N, Kuriyama H, Nagaretani H, Matsuda M, Kondo H, Furuyama N, Kihara S, Nakamura T, Tochino Y, Furuyama N, Matsuzawa Y. Androgen decrease plasma adiponectin, an insulin sensitizing adipocyte derived protein. Diabetes. 2002. 51:2734–2741.
36. Arita Y, Kihara S, Ouchi N, Takahashi M, Maeda K, Miyagawa J, Hotta K, Shimomura I, Nakamura T, Miyaoka K, Kuriyama H, Nishida M, Yamashita S, Okubo K, Matsubara K, Muraguchi M, Ohmoto Y, Funahashi T, Matsuzawa Y. Paradoxical decrease of an adipose-specific protein, adiponectin, in obesity. Biochem Biophys Res Commun. 1999. 257:79–83.
Article
37. Mojiminiyi OA, Abdella NA, Al Arouj M, Ben Nakhi A. Adiponectin, insulin resistance and clinical expression of the metabolic syndrome in patients with Type 2 diabetes. Int J Obes. 2007. 31:213–220.
Article
Full Text Links
  • KDJ
Actions
Cited
CITED
export Copy
Close
Share
  • Twitter
  • Facebook
Similar articles
Copyright © 2024 by Korean Association of Medical Journal Editors. All rights reserved.     E-mail: koreamed@kamje.or.kr